NS-3623

Research use only, not for human use.

A novel human RBC Cl-conductance blocker (IC50=210 nM) and HERG channel activitor (EC50=79.4 uM, HERG1 channel activation).

A novel human RBC Cl-conductance blocker (IC50=210 nM) and HERG channel activitor (EC50=79.4 uM, HERG1 channel activation); inhibits RBC g(Cl) after oral administration to normal mice (ED50= 25 mg/kg), ameliorates erythrocyte dehydration in transgenic SAD mice; increases the macroscopic current conducted by the hERG channels by increasing the time constant for channel inactivation; affects native I(Kr), decreases QT variability and distinctly decreases the occurrence of extrasystoles in the acutely bradypaced hearts.Anemia Discontinued.

——

Animal Model:Anesthetized guinea pigDosage:30 mg/kg Administration:Intravenous injection; lasting for 3 minutes Result:Shortened the corrected QT interval by 25 +/- 4%.

NS 3623 | NS3623

Cell Cycle/DNA Damage

Potassium Channel

Potassium Channel

Other Indications

Anemia

343630-41-1

427.185

C15H10BrF3N6O

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (585.23 mM)

O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(Br)C=C2C3=NNN=N3

N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea

(-20℃)

With Ice Pack

≥ 2 years